Grifols, S.A.

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh

After a turbulent year which began with allegations of fraudulent accounting, Grifols is expecting a bid in the region of €7bn ($7.38bn) from Canada-headquartered investment firm Brookfield which woul

The market for initial public offerings in the US heated up in September with five biopharmaceutical companies launching IPOs, the second busiest month for first-time offerings in 2024 after there wer

Viking Therapeutics ’ share price soared in Q1 as generalist investors continued their landgrab of biopharma companies developing novel obesity therapies. That put it top of the share price gainers am